251 related articles for article (PubMed ID: 15291930)
1. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
De Natale R; Draghi E; Dorigo MT
Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
[TBL] [Abstract][Full Text] [Related]
2. Is more always better?
Tuulonen A
Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
[No Abstract] [Full Text] [Related]
3. Persistence and adherence with topical glaucoma therapy.
Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
[TBL] [Abstract][Full Text] [Related]
6. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
7. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.
Iskedjian M; Walker JH; Desjardins O; Robin AL; Covert DW; Bergamini MV; Einarson TR
Curr Med Res Opin; 2009 Aug; 25(8):1879-88. PubMed ID: 19530975
[TBL] [Abstract][Full Text] [Related]
8. Determinants of adherence to glaucoma medical therapy in a long-term patient population.
Djafari F; Lesk MR; Harasymowycz PJ; Desjardins D; Lachaine J
J Glaucoma; 2009 Mar; 18(3):238-43. PubMed ID: 19295380
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of glaucoma medications.
Rylander NR; Vold SD
Am J Ophthalmol; 2008 Jan; 145(1):106-13. PubMed ID: 18154755
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
[TBL] [Abstract][Full Text] [Related]
11. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
Robin AL; Novack GD; Covert DW; Crockett RS; Marcic TS
Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
13. A gap analysis approach to assess patient persistence with glaucoma medication.
Lee PP; Walt JG; Chiang TH; Guckian A; Keener J
Am J Ophthalmol; 2007 Oct; 144(4):520-4. PubMed ID: 17692273
[TBL] [Abstract][Full Text] [Related]
14. Daily cost of glaucoma medications in China.
Gao Y; Wu L; Li A
J Glaucoma; 2007; 16(7):594-7. PubMed ID: 18091176
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of prostaglandin analogues: a Canadian population-based analysis.
Iskedjian M; Walker JH; Desjardins O; Covert D; Einarson TR
J Med Econ; 2008; 11(2):299-310. PubMed ID: 19450087
[TBL] [Abstract][Full Text] [Related]
16. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Robin AL; Covert D
Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ; Simmons ST; Craven ER
Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
[TBL] [Abstract][Full Text] [Related]
18. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
Br J Ophthalmol; 2002 May; 86(5):551-4. PubMed ID: 11973253
[TBL] [Abstract][Full Text] [Related]
19. Accounting for restart rates in evaluating persistence with ocular hypotensives.
Schwartz GF; Platt R; Reardon G; Mychaskiw MA
Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
[TBL] [Abstract][Full Text] [Related]
20. Use of glaucoma medications: state of the science and directions for observational research.
Lu VH; Goldberg I; Lu CY
Am J Ophthalmol; 2010 Oct; 150(4):569-574.e9. PubMed ID: 20678750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
